Bevacizumab for advanced ovarian cancer treatment. A GRADE based approach
<p><strong>Background: </strong>in advanced ovarian cancer, over the last 10 years no studies have demonstrated more appropriate therapeutic options compared to the current standard Carboplatin-Paclitaxel (Cb-P) regimen. Two phase III randomized studies (GOG-218 36 and ICON-7 37) h...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Milano University Press
2013-03-01
|
| Series: | Epidemiology, Biostatistics and Public Health |
| Online Access: | http://ebph.it/article/view/8826 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850237011778076672 |
|---|---|
| author | Giovanni L. Pappagallo Valter Torri |
| author_facet | Giovanni L. Pappagallo Valter Torri |
| author_sort | Giovanni L. Pappagallo |
| collection | DOAJ |
| description | <p><strong>Background: </strong>in advanced ovarian cancer, over the last 10 years no studies have demonstrated more appropriate therapeutic options compared to the current standard Carboplatin-Paclitaxel (Cb-P) regimen. Two phase III randomized studies (GOG-218 36 and ICON-7 37) have recently demonstrated the efficacy of bevacizumab (recombinant monoclonal antibody that binds with a high affinity to VEGF-A) in adjunct to Cb-P, with 12-15 months maintenance treatment.</p><p><strong>Methods:</strong> the quality of evidence provided was assessed by the use of the GRADE method. Each outcome (deemed to be essential for the purpose of evaluation of the intervention) was assessed to express the degree of confidence in the entity of the beneficial and/or harmful effects of the intervention. Thus, limitations in the quality of conducting the studies (risk of bias), direct applicability/relevance of results to the target population, and precision of results were taken into account.</p><p><strong>Results:</strong> the GOG-218 and the ICON7 study (high-risk subgroup) demonstrated with MODERATE confidence an improvement in critical outcomes PFS and OS, with an absolute reduction of 96 (GOG-218) – 103 (ICON-7) episodes of progression, and 40 (GOG-218) – 135 (ICON-7) deaths per 1 000 patients. A marked increase in risk of hypertension of Grade ≥3 was observed, with an absolute increase of 59 episodes per 1 000 patients in the ICON-7 study, and 157 episodes in the GOG-218 study, respectively, the majority of which were controlled by means of appropriate treatment. The increased risk of other adverse events considered was negligible.</p><p><strong>Conclusions:</strong> the positive effects produced should be viewed as taking prevalence over the negative effects (FAVOURABLE benefit/harm ratio).</p> |
| format | Article |
| id | doaj-art-281dbd1425c2437e99aa83b89af68210 |
| institution | OA Journals |
| issn | 2282-0930 |
| language | English |
| publishDate | 2013-03-01 |
| publisher | Milano University Press |
| record_format | Article |
| series | Epidemiology, Biostatistics and Public Health |
| spelling | doaj-art-281dbd1425c2437e99aa83b89af682102025-08-20T02:01:50ZengMilano University PressEpidemiology, Biostatistics and Public Health2282-09302013-03-0110110.2427/88268492Bevacizumab for advanced ovarian cancer treatment. A GRADE based approachGiovanni L. Pappagallo0Valter Torri1Dipartimento di Scienze Mediche, Ufficio di Epidemiologia Clinica, Azienda ULSS 13 Mirano, VE, ItalyIstituto di Ricerche Farmacologiche “Mario Negri”, Milano<p><strong>Background: </strong>in advanced ovarian cancer, over the last 10 years no studies have demonstrated more appropriate therapeutic options compared to the current standard Carboplatin-Paclitaxel (Cb-P) regimen. Two phase III randomized studies (GOG-218 36 and ICON-7 37) have recently demonstrated the efficacy of bevacizumab (recombinant monoclonal antibody that binds with a high affinity to VEGF-A) in adjunct to Cb-P, with 12-15 months maintenance treatment.</p><p><strong>Methods:</strong> the quality of evidence provided was assessed by the use of the GRADE method. Each outcome (deemed to be essential for the purpose of evaluation of the intervention) was assessed to express the degree of confidence in the entity of the beneficial and/or harmful effects of the intervention. Thus, limitations in the quality of conducting the studies (risk of bias), direct applicability/relevance of results to the target population, and precision of results were taken into account.</p><p><strong>Results:</strong> the GOG-218 and the ICON7 study (high-risk subgroup) demonstrated with MODERATE confidence an improvement in critical outcomes PFS and OS, with an absolute reduction of 96 (GOG-218) – 103 (ICON-7) episodes of progression, and 40 (GOG-218) – 135 (ICON-7) deaths per 1 000 patients. A marked increase in risk of hypertension of Grade ≥3 was observed, with an absolute increase of 59 episodes per 1 000 patients in the ICON-7 study, and 157 episodes in the GOG-218 study, respectively, the majority of which were controlled by means of appropriate treatment. The increased risk of other adverse events considered was negligible.</p><p><strong>Conclusions:</strong> the positive effects produced should be viewed as taking prevalence over the negative effects (FAVOURABLE benefit/harm ratio).</p>http://ebph.it/article/view/8826 |
| spellingShingle | Giovanni L. Pappagallo Valter Torri Bevacizumab for advanced ovarian cancer treatment. A GRADE based approach Epidemiology, Biostatistics and Public Health |
| title | Bevacizumab for advanced ovarian cancer treatment. A GRADE based approach |
| title_full | Bevacizumab for advanced ovarian cancer treatment. A GRADE based approach |
| title_fullStr | Bevacizumab for advanced ovarian cancer treatment. A GRADE based approach |
| title_full_unstemmed | Bevacizumab for advanced ovarian cancer treatment. A GRADE based approach |
| title_short | Bevacizumab for advanced ovarian cancer treatment. A GRADE based approach |
| title_sort | bevacizumab for advanced ovarian cancer treatment a grade based approach |
| url | http://ebph.it/article/view/8826 |
| work_keys_str_mv | AT giovannilpappagallo bevacizumabforadvancedovariancancertreatmentagradebasedapproach AT valtertorri bevacizumabforadvancedovariancancertreatmentagradebasedapproach |